- Conditions
- Obesity
- Interventions
- Exenatide, Placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 12 Years to 19 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Saint Paul, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 841–864
of 1,163
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rheumatoid Arthritis
- Interventions
- Sarilumab, Etanercept, Methotrexate, Placebo (for sarilumab), Placebo (for etanercept), Adalimumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 776 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Glendale, California • Thousand Oaks, California + 27 more
- Conditions
- Asthma
- Interventions
- SAR231893, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 12
- States / cities
- Bakersfield, California • Culver City, California • Los Angeles, California + 9 more
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- Efimosfermin, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 34 more
- Conditions
- Hepatitis C
- Interventions
- Alisporivir, Peginterferon alfa-2a, Ribavirin, ALV Placebo
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,081 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 32
- States / cities
- Beverly Hills, California • Oakland, California • San Diego, California + 23 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Lixisenatide (AVE0010), Placebo, Pen auto-injector
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Ankylosing Spondylitis
- Interventions
- Sarilumab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Anaheim, California • Los Angeles, California + 23 more
- Conditions
- Hypereosinophilic Syndrome
- Interventions
- Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 7
- States / cities
- San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more
- Conditions
- Optic Neuritis
- Interventions
- Efgartigimod Alfa, Placebo
- Drug
- Lead sponsor
- Anastasia Vishnevetsky, MD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Rheumatoid Arthritis
- Interventions
- Placebo for Adalimumab, Adalimumab, Placebo for Upadacitinib, Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,629 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 109
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 83 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 935 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 92
- States / cities
- Cullman, Alabama • Jasper, Alabama • Scottsboro, Alabama + 79 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Izokibep, Placebo to izokibep
- Drug
- Lead sponsor
- ACELYRIN Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Encino, California • Fountain Valley, California + 16 more
- Conditions
- Crohn Disease
- Interventions
- Placebo for Ustekinumab, Placebo for Adalimumab, Ustekinumab (6 mg/kg), Ustekinumab (90 mg), Adalimumab (40 mg)
- Biological
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 67
- States / cities
- Mobile, Alabama • San Diego, California • Colorado Springs, Colorado + 60 more
- Conditions
- Hidradenitis
- Interventions
- Duvakitug, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Miami, Florida
- Conditions
- Venous Thromboembolism
- Interventions
- Open-label Semuloparin sodium, Placebo (for Semuloparin sodium), Semuloparin sodium
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Hypoglycemia, Diabetes Mellitus, Type 1
- Interventions
- Dasiglucagon, Placebo
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Chula Vista, California • Escondido, California • Renton, Washington
- Conditions
- Persistent Asthma
- Interventions
- German cockroach allergenic extract, Placebo for German cockroach allergenic extract
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
- Conditions
- Osteoporosis, Postmenopausal Osteoporosis
- Interventions
- Placebo, BA058 80 mcg, teriparatide
- Drug
- Lead sponsor
- Radius Health, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years · Female only
- Enrollment
- 2,463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 5
- States / cities
- Lakewood, Colorado • Miami, Florida • North Miami, Florida + 2 more
- Conditions
- Facial Pain, Rhinosinusitis
- Interventions
- Erenumab Prefilled Syringe, Placebo
- Drug · Other
- Lead sponsor
- David Jang, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- HIV-1-infection
- Interventions
- SAR441236, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
- Conditions
- Type 1 Diabetes, Preservation of Insulin Secretion, Newly Diagnosed Type 1 Diabetes, Canakinumab in Type 1 Diabetes
- Interventions
- canakinumab (anti IL-1beta), Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 6 Years to 45 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 11
- States / cities
- San Francisco, California • Stanford, California • New Haven, Connecticut + 8 more
- Conditions
- Relapsing Multiple Scelrosis
- Interventions
- Ofatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule, Matching placebo of ofatumumab subcutaneous injections
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 955 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 51 more
- Conditions
- Partial Lipodystrophy
- Interventions
- metreleptin, Placebo
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Sacramento, California • Boca Raton, Florida + 9 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Parenteral Insulin, Close Observation, Oral Insulin, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 3 Years to 45 Years
- Enrollment
- 711 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1994 – 2003
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 10 more